EntryPoint Capital’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$756K Buy
+83,961
New +$1.32M 0.22% 113
2024
Q4
Sell
-18,331
Closed -$366K 697
2024
Q3
$366K Buy
18,331
+11,898
+185% +$185K 0.21% 160
2024
Q2
$71.9K Buy
6,433
+1,693
+36% +$14.2K 0.11% 441
2024
Q1
$31.3K Buy
+4,740
New +$25.9K 0.03% 940

Other funds holding ADMA

EntryPoint Capital's ADMA Position: Q1 2026 in Review

EntryPoint Capital opened a new position in ADMA Biologics (ADMA) in Q1 2026: 83,961 shares worth $756K. The stake represents 0.22% of the portfolio and ranks #113 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in ADMA as recently as Q3 2024.

EntryPoint Capital first reported a position in ADMA in Q1 2024 and has held it in 4 quarters since. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • EntryPoint Capital held 83,961 shares of ADMA Biologics worth $756K as of Q1 2026.
  • ADMA Biologics was a new EntryPoint Capital position in Q1 2026.
  • ADMA Biologics made up 0.22% of EntryPoint Capital's portfolio in Q1 2026, its #113 holding.
  • EntryPoint Capital first reported a position in ADMA Biologics in Q1 2024 and has held it in 4 quarters since.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.